Kaveri Therapeutics Inc.Private▲ Positive
Capitalrelevance
Kaveri Therapeutics receives seed funding and exclusive rights to two oncology programs from Lupin, with experienced leadership appointed.
Lupin Limited has transferred two oncology programs, LNP7457 and LNP8701, into newly formed U.S.-based Kaveri Therapeutics Inc. Under the deal, Lupin's wholly owned subsidiary Lupin Inc. retains a significant equity stake in Kaveri, provides seed funding, and grants exclusive rights to the programs. Kaveri will operate independently under CEO Kristi Jones and Chief Medical Officer Dr. Robert Pierce. Both assets have shown encouraging early clinical results at ASCO meetings, with Phase 1b trials planned for each.
Kaveri Therapeutics receives seed funding and exclusive rights to two oncology programs from Lupin, with experienced leadership appointed.